The GPER1 Knockout 769-P Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population specifically designed to disrupt the GPER1 gene in the 769-P human cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, resulting in the ablation of functional GPER1 protein expression. The polyclonal pool provides a heterogeneous but enriched knockout population, enabling robust analysis of GPER1-dependent signaling without the clonal artifacts associated with single-cell-derived lines. Researchers can employ this system to dissect the rapid, non-genomic estrogen signaling pathways that are often superimposed on classical nuclear receptor activity, particularly in cancer contexts where GPER1 cross-talk with growth factor receptors significantly alters cellular behavior.
Derived from a primary clear cell renal cell carcinoma, the 769-P cell line serves as a well-established model of human renal cell carcinoma. This adherent epithelial line retains key features of the originating tumor, including histological and molecular characteristics of clear cell carcinoma, the most common subtype of renal cancer. Its genetic background and culture adaptability make it a preferred choice for investigating oncogenic mechanisms, drug responses, and signal transduction in a setting that recapitulates the parental tumor microenvironment. By introducing a GPER1 knockout into this renal carcinoma background, the system permits direct interrogation of estrogen-mediated processes that may contribute to tumor progression, metastasis, or therapeutic resistance in a disease context where hormonal influences are increasingly recognized.
GPER1 functions as a G protein-coupled receptor that mediates rapid estrogen signaling, responding to ligands such as 17??-estradiol and the selective agonist G-1, while the antagonist tamoxifen can attenuate its activity. Upon activation, GPER1 couples to G??s and G??i/o proteins, triggering Src kinase-mediated transactivation of the epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-1R). This initiates downstream cascades including the Ras?CRaf?CMEK?CERK1/2 pathway and the PI3K?CAkt axis, leading to phosphorylation of ERK1/2 and Akt and subsequent transcriptional upregulation of target genes such as c-Fos and Cyclin D1. Additionally, GPER1 signaling modulates matrix metalloproteinase-9 (MMP-9) expression, influencing cell migration. The receptor also interacts with ??-arrestins, which scaffold additional signaling modules and influence receptor trafficking. Cross-talk with growth factors like EGF and IGF further amplifies these pathways. Knockout of GPER1 eliminates these rapid signaling events, directly impacting cAMP levels, PKA activity, and the dynamics of the MAPK/ERK and PI3K/Akt networks.
In the context of 769-P clear cell renal cell carcinoma, GPER1-mediated pathways may drive key oncogenic phenotypes such as proliferation, migration, and survival. Estrogen signaling through GPER1 has been implicated in the progression of various hormone-responsive cancers, and its role in renal cell carcinoma is an emerging area of investigation. The absence of GPER1 in this model allows researchers to specifically assign these functional outputs to the GPER1 axis, distinguishing them from nuclear estrogen receptor activities. This is critical for understanding how estrogenic stimuli in the renal tumor microenvironment??whether from circulating hormones, local production, or therapeutic agents like tamoxifen??shape tumor biology. The polyclonal knockout cells thus provide a physiologically relevant platform to delineate GPER1??s contribution to renal cancer progression and to test whether targeting this receptor can restrain malignant behavior.
This product supports a wide range of experimental applications, including the investigation of estrogen-mediated signaling in renal cell carcinoma and the evaluation of GPER1-targeted therapies. Typical assays include Western blotting to confirm knockout and assess phospho-ERK1/2 or phospho-Akt levels, RT-qPCR for downstream gene expression (e.g., c-Fos, Cyclin D1), and functional studies such as MTT or BrdU proliferation assays, wound-healing and transwell migration assays, and apoptosis detection. Estrogen stimulation experiments using 17??-estradiol or G-1 can be combined with pharmacological inhibitors to dissect pathway contributions, while drug sensitivity assays against tamoxifen or other endocrine agents aid in modeling endocrine resistance. For further details on this GPER1 knockout model, please contact Ascent Research.
